**Name of journal:** ***World Journal of Gastroenterology***

**Manuscript NO: 35161**

**Manuscript type: Review**

**Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh, and Malaysia: A review**

Rahman MM *et al*. IBS in India, Bangladesh, and Malaysia

M Masudur Rahman, Sanjiv Mahadeva, Uday C Ghoshal

**M Masudur Rahman,** Department of Gastroenterology, Dhaka Medical College and Hospital, Dhaka 1000, Bangladesh

**Sanjiv Mahadeva,** Division of Gastroenterology, Department of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia

**Uday C Ghoshal,** Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India

**ORCID number:** M Masudur Rahman (0000-0002-9713-2223); Sanjiv Mahadeva (0000-0003-0021-8596); Uday C Ghoshal (0000-0003-0221-8495).

**Author contributions:** Rahman MM reviewed the literature and wrote the first draft of the paper; Mahadeva S contributed to writing the paper and edited it; Ghoshal UC conceived the idea, reviewed the literature and contributed to writing the paper and edited it extensively.

**Conflict-of-interest statement:** None of the authors has any conflict of interest to declare in relation to the paper.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Uday C Ghoshal, MD, DNB, DM, FACG, RFF, Professor,** Department of Gastroenterology**,** Sanjay Gandhi Postgraduate Institute of Medical Science**,** Lucknow 226014, India. udayghoshal@gmail.com

**Telephone:** +91-522-2494405

**Fax:** +91-522-2668078

**Received:** June 23, 2017

**Peer-review started:** June 26, 2017

**First decision:** july 27, 2017

**Revised:** August 23, 2017

**Accepted:** September 13, 2017

**Article in press:**

**Published online:**

**Abstract**

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder in clinics and in the community. It has a significant impact on both the society and patients' quality of life. The epidemiology, clinical presentation, and management of IBS may vary in different geographical regions due to differences in diet, gastrointestinal infection, socio-cultural and psycho-social factors, religious and illness beliefs, symptom perception and reporting. Although previous reviews and consensus reports on IBS in Asia have been published, Asia is quite diverse socio-demographically. In this context, India, Bangladesh, and Malaysia share some similarities: (1) a large proportion of the population live in rural areas, (2) there is rapid development and associated lifestyle changes in urban areas, and (3) their populations share some similar dietary, cultural and religious practices. The present review aims to explore clinical and epidemiological data on IBS from these three major nations in South and South-East Asia. In depth review of the literature revealed important differences between IBS in the east, as revealed by studies from these three countries, and the West; these include a predominantly rural profile, differences in bowel habit and symptom profile raising concern with regards to diagnostic criteria and subtyping IBS, higher dietary fiber consumption, frequent lactose malabsorption, parasitosis, and possible overlap between post-infectious IBS and tropical sprue. Moreover, current perception on difference in prevalence of the disorder in these countries as compared to the West might be related to variation in survey methods.

**Key words**: Irritable bowel syndrome; functional gastrointestinal disorders; epidemiology; Asia; symptom; constipation; diarrhea

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The epidemiology, clinical presentation and management of irritable bowel syndrome (IBS) may vary in different geographical regions due to differences in diet, gastrointestinal infection and infestations, socio-cultural and psycho-social factors, religious and illness beliefs, symptom perception and reporting. Asia is geographically and socio-demographically diverse. In this context, India, Bangladesh and Malaysia share some similarities: (1) large population live in rural areas; (2) there is rapid development and associated lifestyle changes in urban areas; and (3) similar dietary, cultural and religious practices. The present review aims to explore clinical and epidemiological data on IBS from these three major nations in South and South-East Asia.

Rahman MM, Mahadeva S, Ghoshal UC. Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh, and Malaysia: A review. *World J Gastroenterol* 2017; In press

**INTRODUCTION**

Irritable bowel syndrome (IBS) is a bowel disorder in which chronic abdominal pain or discomfort (the latter has been removed in the Rome IV criteria) is associated with irregularity in the stool form and passage in the absence of any organic cause[1]. IBS has a significant impact on patients' quality of life due to physical suffering, psychological co-morbidity, social disability and economic non-productivity[2,3]. Though the global pooled prevalence of IBS has been estimated to be 11.2%[4], this figure has been questioned due to significant heterogeneity in published studies[5]. The prevalence, however, may be lower in the East. As the pathophysiology of IBS is poorly understood, the management generally focuses on the amelioration of symptoms and improvement in the quality of life. At present, the drugs available for the treatment of IBS have only a modest effect on symptom improvement and may not alter the natural history of the condition. The management strategy recommends a positive diagnosis, consideration of the patients’ perspective, development of a good doctor patient relationship, identification of contributing factors, critical appraisal of the efficacies of various drugs according to the subtype of IBS and continuing care[6-8].

In view of the recent and growing interest in the gut microbiome and GI diseases, including IBS, data from Asian research (where infection and infestations are common) may be able to offer specific epidemiological insight. Although previous reviews and consensus reports on IBS in Asia have been published[8],Asia remains a geographically and socio-demographically diverse region. Furthermore, a significant portion of the population in Asia live in rural areas, but data from rural epidemiological studies are scanty. In this context, India, Bangladesh and Malaysia, three major nations in the South and South East region of Asia, share some similarities: (1) significant proportions of their populations reside in rural areas; (2) there is rapid development and associated lifestyle changes in urban areas; and (3) dietary, cultural and religious practices are somewhat similar. Another similarity between these three countries is the language used for medical education and scientific publications. Since the medical education in these three countries are in the English language and the scientific studies are also published in English, local languages were not needed for data extraction from published literature. Hence, the present review aims to explore clinical and epidemiological data on IBS from a South and South-East Asian perspective.

**EPIDEMIOLOGY**

***Prevalence***

Several population-based studies have been conducted to explore the epidemiology of IBS in India, Bangladesh, and Malaysia using different diagnostic criteria (Table 1 and Figure 1). In contrast to several studies from the West, most of which are either internet and telephone surveys with their inherent bias, the majority of these studies were house to house surveys. Based on these studies, the reported prevalence of IBS varies from 4.2%-7.5%; 7.7%-12.9% and 11%-14% in India[9-12], Bangladesh[13-15], and Malaysia[16,17], respectively.

In addition to the studies summarized in Table 1, a few house to house surveys, conducted primarily on chronic constipation, provided data on constipation-predominant IBS as well. In a house to house survey among 505 subjects aged 9-64 years from Chandigarh, India the prevalence of constipation by Rome II was 16.8%[18]. In another Indian study among 925 constipated patients presenting to general physicians, 75.6% had functional constipation and 24.4% had IBS-C[19]. It has been reported that the prevalence of IBS in Asian countries is rising, with more developed nations, such as Japan and Singapore, documenting a comparable prevalence to that in western countries[20]. These data might suggest that IBS may be related to economic development associated with lifestyle changes, fast living, psychological stress associated with reduced T regulatory cell response. However, the differences in prevalence across the three countries and within the countries may be a result of variation in the diagnostic criteria used, socio-demographic differences in the populations studied, survey methods and the study instrument. A previous systematic review and meta-analysis of 260960 subjects from 80 studies across the Globe suggested that the pooled prevalence of IBS of all studies was 11.2% (95%CI: 9.8%-12.8%)[4]. However, a more recent systematic review and meta-analysis demonstrated that the estimation of global prevalence of IBS may be inaccurate due to significant heterogeneity between the studies[5].

***Urban vs rural prevalence***

An urban lifestyle is reported to be associated with greater psychological stress, and thus may be associated with a higher prevalence of IBS compared to rural living. Community-based epidemiological studies on IBS have been published both from the urban and rural population in India, Bangladesh, and Malaysia. Rural surveys in India have demonstrated an IBS prevalence of 4.2% (Rome III criteria) among 2774 subjects in three villages of Uttar Pradesh, the northern part of India[12], and 4% (Rome III criteria) in another northern Indian study[11]. In Bangladesh, an IBS prevalence of 8.5% (Rome I criteria) was reported in a rural household survey among 2426 subjects[13]. In the East Coast of Peninsular Malaysia, a 10.9% prevalence of IBS (Rome III criteria) was documented among rural subjects of Malay ethnicity [17].

Interestingly, urban surveys in these 3 countries did not show a significant variation in the prevalence of IBS from the rural communities. A 7.7% prevalence of IBS (using the Manning criteria) was observed among 2549 randomly selected subjects in urban Mumbai, India[9], while an IBS prevalence of 7.7% (Rome II criteria) was reported in a survey of 1503 adult subjects in Dhaka city, Bangladesh[14]. In the West Coast of Peninsular Malaysia, investigators reported a relatively high prevalence rate of IBS at 14% (Rome II criteria) among 1179 multi-ethnic adult subjects in an urban setting, but not much higher than the previous rural study[17]. In this multi-ethnic study, there were no differences in prevalence among ethnic Malays, ethnic Chinese and ethnic southern Indians, who were of comparable socio-demographic status [17].

The observations from these studies in South Asia appear to contrast with reports, which indicate that IBS is more common in urban as compared to rural populations [21-23]. Population-based studies comparing prevalence of IBS in urban and rural communities have shown differences in China (urban 10.5% *vs* rural 6.14%)[21], Israeli Bedouins ((9.4% *vs* 5.8%, *p* < 0.01)[22] and Italy (urban 9.9% *vs* rural 4.4%)[23]. It is uncertain if the lack of difference in IBS prevalence between urban and rural communities highlighted in this review of Indian, Bangladeshi and Malaysian studies is related to lack of head-to-head comparison using uniform diagnostic criteria and study design. Furthermore, previous population studies in Malaysia, using similar methodologies and diagnostic criteria (Rome II) have shown significant differences in the prevalence of uninvestigated dyspepsia between urban and rural communities[24].

***Gender issues***

Early institution-based studies from India showed that IBS was two to four times more common among male compared to female adults[25-27] but subsequent population-based studies revealed mixed findings. The male: female ratio in the prevalence of IBS in India, Bangladesh, and Malaysia are highlighted in Table 1. It is important to note that all these studies that reported female predominance from these three Asian countries, female to male ratios were as not as wide as reported from the West. The lack of an obvious female predominance amongst IBS subjects appears to be common in several Asian reports[8,20,28-30]. This is in contrast to the studies from the West, which consistently reported 2-3 times greater prevalence of IBS in women than in men[3]. Although a meta-analysis of community-based studies reported that IBS is 67% higher in females compared to males (OR = 1.67; 95%CI: 1.53-1.82), no significant gender differences were observed in South Asia[4]. A recent meta-analysis on a Global prevalence of IBS found that the pooled prevalence rates were higher among female (10.2%) compared to male (8.8%). The prevalence rates of IBS were higher among female than male in each region of the Globe separately[5]. However, as the authors of this meta-analysis acknowledged that due to significant heterogeneity in the number of available studies in different parts of the world and the methods, pooled estimates are expected to be biased.

**SYMPTOM PROFILE AND DIAGNOSIS OF IBS**

The Rome criteria are currently the most widely accepted for establishing a diagnosis of IBS. However, studies from India and Bangladesh have reported that frequency and/or severity of abdominal pain, a cardinal symptom in the Rome criteria, may not be so common among their population with IBS. A multi-centric study involving 2785 patients visiting physicians at 30 centers across India with chronic lower gastrointestinal symptoms, no `alarm features` and negative investigations for organic causes has been published; in this study, abdominal pain and discomfort was present in only 70% of subjects[10]. Other institution-based studies from India on IBS subjects have reported abdominal pain in a range from 33%[31] to 70%[32]. As abdominal pain is a pre-requisite for the symptom-based diagnosis of IBS by the Rome criteria, these criteria may have a low sensitivity for diagnosing IBS in India. In another multi-center, Indian study (MIIBS) using various diagnostic criteria for IBS, the Manning criteria had the highest sensitivity (91%), followed by Asian criteria (74.5%), Rome I (68%), Rome III (52.5%) and Rome II (40%) to diagnose IBS[33]. The higher sensitivity of the Manning and Asian criteria might have been due to the fact that "abdominal pain" was not absolutely necessary for the diagnosis of IBS by both of these criteria. Furthermore, "abdominal bloating" had been included in combination with "abdominal pain or discomfort" by the Asian criteria[8]. When multiple diagnostic criteria were applied in a rural population in Bangladesh, IBS prevalence of 1.8%, 7.3%, 8.8%, and 7.7% was found using Manning ≥ 3, Manning ≥ 2, Rome I and Rome II criteria, respectively. The IBS prevalence varied according to the criteria applied, with rates as high as 27.9% using "Manning ≥ 2" without pain, and down to 1.8% using "pain with Manning ≥ 3"[34]. A systematic review previously demonstrated that the Rome II criteria had a poor sensitivity for diagnosing IBS in primary care, ranging between 31% to 65%, with the lowest sensitivity rates derived from studies in India[35]. The lack of accuracy of a symptom-based criterion for diagnosing IBS may be more relevant for patients in India and Bangladesh for at least two reasons. Firstly, IBS patients often do not report abdominal pain as the predominant symptom in this region. Secondly, these criteria were originally developed and validated in Western populations, who are known to differ from Eastern populations with regard to socio-cultural issues, language, symptom perception and epidemiology[36]. Considering the fact that the Rome IV criteria did not include even abdominal discomfort or bloating as the essential symptom to diagnose IBS (Table 2), the sensitivity of the Rome IV criteria is expected to be lower in these three countries[37].

A recent study by the Rome Foundation-Asian working team[38] on 1805 consecutive unselected FGID patients presenting to the primary or secondary care centers in 11 Asian centers using a culturally adapted Rome III Diagnostic Questionnaire initially translated and validated in 9 Asian languages[39,40] identified 9 symptom clusters by principal component factor analysis with varimax rotation. Authors concluded that though IBS and chronic constipation were the dominant symptom clusters, bowel symptom cluster with meal trigger and a gas cluster were the other prominent groups that were in line with the old Asian concept that identified epigastric localization of pain, and emphasized meal and gas related symptoms[41].

***Upper abdominal symptoms and overlap with functional dyspepsia in IBS***

IBS and functional dyspepsia (FD) have common pathophysiological mechanisms like visceral hypersensitivity, central abnormal processing of sensory perception, GI dysmotility, and psychological factors; these two disorders are, therefore, are expected to coexist[42]. Figure 2 shows the prevalence of IBS-FD overlap, IBS, and FD in three population-based studies in India and Bangladesh[9,12,15]. These population-based studies from India and Bangladesh demonstrated that 3.5% to 4.5% of the general adult population of India and Bangladesh have dyspepsia-IBS overlap (Figure 2). In a community-based survey among 3000 rural and urban population in a district of Bangladesh, 42% of FD subjects had IBS and 27% IBS subjects had FD. Overall, bowel symptom frequency scores were higher in IBS-FD than IBS alone (10.01 ± 4.17 *vs* 8.16 ± 3.84; *p* < 0.000)[15]. In an urban survey of adults from Malaysia, subjects with IBS were more likely to report symptoms of GERD compared to healthy controls (56% *vs* 29%, OR = 3.06)[16]. Environmental factors such as diet may be a contributory factor for upper GI symptoms in IBS sufferers in South Asians. In a study in Mumbai, India, > 99% of the population consumed chili in their diet and 75% of subjects consumed it in a moderate to high quantity[9]. Chili is known to aggravate not only IBS symptoms[43] but has been shown to independently predict dyspepsia in a multi-ethnic population in Malaysia[44]. Furthermore, GERD and *H. pylori* infection are recognized to be more prevalent among ethnic Indians/South Asians compared to other ethnic groups in Asia[45,46]. It is likely that these factors may lead to a greater overlap of IBS-FD and IBS-GERD among South Asians compared to other ethnic groups in Asia.

**SUBTYPING OF IBS**

IBS sub-classification into diarrhea- and constipation-predominant are important for determining appropriate therapeutic strategies. However, studies in India, Bangladesh and Malaysia have reported that the majority of IBS patients could not be easily classified into distinct sub-types. In a multi-centric Indian study, 53% and 47% of 2656 subjects with lower gastrointestinal symptoms had subjective perceptions of constipation and diarrhea, respectively[10]. However, when stool frequency-based criteria of constipation (stool frequency < 3/wk) and diarrhea (stool frequency > 3/d) were applied to the same subjects, 19% had constipation, 4% had diarrhea and 57% had indeterminate symptoms. In this study, the median stool frequency was similar (2 times/d) in patients who had perceived themselves to have either constipation or diarrhea[10]. In a rural community-based study at Uttar Pradesh, northern India, 83% of the IBS subjects remained unclassified using the Rome III criteria. Interestingly, the application of Asian criteria, instead of the Rome III criteria, reduced the indeterminate sub-type of IBS subjects in rural India from 83% to 12%[12]. Similarly, the MIIBS study of 1618 subjects with lower gastrointestinal symptoms found that by stool frequency criteria, 78% subjects remain unclassified whereas by patients` perception and stool form (Bristol stool scale) criteria only 28% and 16% patients remain unclassified, respectively[33]. In a rural study in Bangladesh, 64% of IBS subjects diagnosed by the Rome II criteria could not be sub-typed[13]. In Malaysia, a rural survey of ethnic Malays similarly demonstrated that the majority of IBS subjects fell into a “mixed” category with the Rome III criteria as follows: 20.8% IBS-C, 16.7% IBS-D and 58.3% mixed pattern[17]. These studies suggest that several popularly used criteria may be poor at classifying IBS into constipation- and diarrhea-predominant types in Asia. Community-based studies in India and Bangladesh have shown that > 90% of the general population have a bowel motion of at least once per day[10,47,48]. These differences in bowel habit between South Asians and Westerners may be due to differences in dietary pattern, fiber intake, intestinal transit time and frequency of lactose malabsorption as compared to the Western population[49]. In a study from India, the mean fiber intake was found to be similar at 52 g in both IBS and healthy controls[50]. This is higher than the recommended daily fiber intake (20-30 g in adults) and actual daily dietary fiber intake (13.3 g) in the West[51-53]. Furthermore, the mean intestinal transit time of 39.85 h among northern Indians contrasts significantly to that of 83.4 hours in a Caucasian adult [54].

**PATHOPHYSIOLOGICAL INSIGHTS**

***Inflammation and IBS***

Current evidence suggests that the pathogenesis of IBS is multi-dimensional consisting of gut microbial dysbiosis including small intestinal bacterial overgrowth (SIBO), visceral hypersensitivity, intestinal mucosal immune activation, dietary intolerance, increased intestinal permeability, abnormal gut-brain interaction including cognitive dysfunction, psychosocial distress and altered gastrointestinal motility[55-57]. Low-grade inflammation plays a major role in the pathophysiology in a subset of patients with IBS[57]. This has been explored in several studies in India, Bangladesh, and Malaysia. IBS patients in a tertiary care hospital in Bangladesh were found to have a significant increase in chronic inflammatory cells, mast cells and lymphoid follicles compared to control group of healthy subjects (*p* < 0.05). Mast cells but not the number of chronic inflammatory cells, mucosal and submucosal lymphoid follicles, were significantly increased in PI-IBS than non-PI IBS in this study[58]. These findings concur with similar reports in Western IBS patients[56,59]. Mast cell activation is associated with epithelial and neuromuscular dysfunction, visceral hypersensitivity, increased epithelial permeability and altered motility[56,59].

In an Indian case-control study including 221 patients with IBS and 273 age- and gender- matched controls, an interleukin-1 (IL-1) receptor antagonist under-producer genotype was associated with IBS and its over-producer protective. Moreover, higher levels of IL-1α and IL-1β were found in patients with SIBO, and IL-1α and IL-1β was associated with bloating and loose stools. The findings of this study clearly show the role of inflammation in the pathogenesis of IBS in general and diarrhea-predominant IBS, in particular[60]. Several case-control studies, though under-powered, on genetic polymorphisms in candidate pro-, anti-inflammatory and xenobiotic metabolizing genes support the role of inflammation in the pathogenesis of IBS[61-64].

Imbalance in body serotonin, 95% of which is in the gut, plays a major role in the pathogenesis of IBS, with its deficiency contributing to slow gut transit and constipation and excess causing diarrhea[65]. In an Indian case-control study, SLC6A4 was found as a potential candidate gene involved in the pathogenesis of IBS[66]. The frequency of SLC6A4 polymorphism and higher levels of 5HT were significantly associated with IBS[66].

The association between microscopic colitis (MC) and IBS has similarly been described. In a recent systematic review and meta-analysis, the pooled prevalence of MC in Western IBS patients was 7.2% (95%CI: 1.5%-17.2%) and the prevalence varied between 2.4% to 11.5% in individual studies[67]. In the only report from Bangladesh, lymphocytic colitis (LC) was found in 37% of 60 patients with diarrhea-predominant IBS, with a complete absence of collagenous colitis. The distribution of LC was restricted in proximal colon in 68.2% patients, in the left colon in 9.1%, and diffuse in 22.7%[68]. A study of 120 subjects in a Malaysian tertiary institution found a very low (1.3% only) prevalence of collagenous colitis among 120 IBS subjects. However, IBS-D patients had a higher prevalence of moderate non-specific, microscopic inflammation compared to controls (14.9% *vs* 2.2%, *p* = 0.005), suggesting that either occult infection or other causes of inflammation may be contributory towards IBS-D sub-types[69]. In an Indian case series on 29 patients with MC presenting with chronic large bowel diarrhea, of 7, 4, 7 and 11 patients with collagenous colitis, LC, minimal change colitis and microscopic colitis not otherwise specified 28.6%, 25%, 14.3%, and 33.3% had abdominal discomfort suggesting that they would fulfill the Rome III criteria for IBS[70]. In another Indian study among 400 patients with chronic watery diarrhea, 3.7% had microscopic colitis (33% had collagenous colitis and 67% had lymphocytic colitis) and 10/15 of these patients were clinically diagnosed as IBS[71]. Data from the institutional-based studies suggest that MC is rare amongst South and South-East Asian IBS patients, perhaps in-keeping with the lower prevalence of inflammatory bowel disease (IBD) in this region[72].

***Protozoa and IBS***

The presence of *E. histolytica* in the stool of a patient with chronic lower gastrointestinal symptoms creates confusion among physicians and they often label the patients as suffering from chronic non-dysenteric amebic colitis. A multi-centric study on IBS from India showed that of 1237 patients reporting treatment with metronidazole in the past, 672 (24%) experienced temporary improvement[10]. Two studies in India explored this issue among IBS patients[73,74]. No significant differences were found in the proportion of *E. histolytica* in the stool (18% *vs* 18%), serologic evidence of infection (42% *vs* 41%), colonoscopic abnormalities (7% *vs* 3%) or histologic abnormalities among 144 IBS and 100 asymptomatic subjects. Additionally, there was no significant difference in response to therapeutic trial with metronidazole among the symptomatic patients who were cyst positive or negative at 6 mo[73]. In the second study of 154 inmates of a leprosy rehabilitation center, *E. histolytica* positivity among IBS and controls were found to be 50% and 19%, respectively. All strains of amoeba isolated were found to be non-pathogenic and there was no relationship between *E. histolytica* and symptoms of IBS at 12 mo follow-up[74]. These studies suggest that non-pathogenic *E. histolytica* is an innocent by-stander in IBS subjects, which are inappropriately termed as “chronic amoebiasis“and often treated with anti-amoebic drugs unnecessarily.

Another common gut parasites found in the intestinal tract of humans and animals, Blastocystis sp, has been associated controversially with IBS, possibly as a result of irregular shedding of parasites in stool and variation in fecal detection. A recent study examining for parasitic infestations using PCR techniques reported a significantly higher prevalence of Blastocystis species (17% *vs* 5.5%), corroborated by increased cytokines for inflammation (IL-3, IL-5, and IL-10) in IBS patients compared to healthy controls in Malaysia[75]. Furthermore, IBS patients with increased stool frequency were found to have a greater quantity of Blastocystis cysts, indicating that the severity of IBS symptoms correlated with the quantity of parasitic infestation[76]. These studies from Malaysia indicate that persistent chronic parasitic infection, which is often undetectable using standard culture or laboratory techniques, may be an additional contributory factor to microscopic gut inflammation in IBS in Asians.

In the light of these observations of protozoal diseases among South and South East Asian patients with IBS, it is not surprising that a multi-centric Indian study showed that 44% of the subjects with chronic lower GI symptoms took metronidazole with temporary symptom improvement among 54% of them[10]. Additionally, a randomized placebo controlled trial among 45 IBS subjects who were allocated to ispaghula husk (60 d), metronidazole (metronidazole 10 d and placebo 50 d) and placebo (60 d) found that metronidazole provided symptom relief in IBS compared to placebo without affecting recto-sigmoid motility[77].

***Helminthiasis and IBS***

Helminthic infestation is common in Bangladesh and India. In a report from rural Bangladesh, 70% of 252 children had been found to have soil-transmitted helminthiasis by the age of 2 years[78] . In southern India, a report suggested that 62% of all age groups had hookworm infestations[79]. Intestinal helminthiasis causes a shift in the immune system towards a T-helper 2 cell response[80,81]. This may be associated with a low-grade, protracted inflammation, which is recognized in a subset of IBS patients. Previous reviews have speculated that a high intestinal helminthic/parasitic infestation may be the cause of a low prevalence of IBS in spite of a high incidence of acute infective diarrhea in Asia[82]. Furthermore, the “hygiene hypothesis” speculates that a high childhood infection is responsible for the low prevalence of IBS in the developing countries.

***PI-IBS and PI-MAS***

PI-IBS has been defined as an acute onset IBS (by Rome criteria) that develop after the individual, who has not previously met the Rome criteria, experiences a gastrointestinal infection with two or more of the following characteristics: fever, vomiting, diarrhea, and a stool culture positive for an infectious agent[83,84]. The pooled incidence of PI-IBS was found to be 10% in a systematic review and meta-analysis of predominantly Western studies[85]. Data on PI-IBS from Asian countries are scanty where acute gastroenteritis is common[86]. Studies from China and Korea have revealed that the incidence of PI-IBS is 8%-15%[87,88]. The incidence rate for acute diarrhea among those aged > 14 years in parts of India and Bangladesh have been reported as 60 per 100 person-years and between 15.2 to 135.7 per 100 person-years, respectively[89-91]. Despite a high incidence rate of acute diarrhea in the Indian subcontinent, there is no published study on PI-IBS. Furthermore, the relatively low prevalence of IBS in the Indian subcontinent, despite a high burden of acute diarrheal illness, appears enigmatic[83,86]. However, a condition similar to PI-IBS, post-infectious malabsorption (PI-MAS) or tropical sprue has been recognized in the Indian sub-continent for some time. A prevalence rate of 8%-20% of PI-MAS was previously reported in rural southern India following an episode of acute infectious diarrhea[92]. Both PI-IBS and PI-MAS have similar clinical features, etiopathogenesis, and potential response to treatment with antibiotics[93]. Furthermore, both PI-IBS and PI-MAS have been associated with SIBO[94,95] and abnormal small intestinal permeability[96]. It is likely then, as IBS is a symptom-based diagnosis, that patients with mild malabsorption syndrome can be misdiagnosed as IBS, particularly of diarrhea-predominant type, unless malabsorption is carefully excluded by appropriate investigations. In most studies on PI-IBS, PI-MAS has not been carefully excluded using tests for malabsorption. Considering the fact that PI-MAS or tropical sprue has been described recently following an attack of acute infectious diarrhea in developed countries like the United States, this issue needs consideration in developed and temperate countries as well[97]. Hence, there may be some overlap between PI-IBS and PI-MAS in the Indian sub-continent[83,86,96] andsome cases of PI-MAS may be erroneously diagnosed as cases of PI-IBS. In a recent study from Dhaka, Bangladesh, 10% of 23 patients with acute gastroenteritis fulfilling Rome III criteria for IBS in absence of previous IBS were found to have PI-MAS on investigation[98].

***SIBO and IBS***

SIBO and IBS have similar clinical features. Routine investigations conducted to exclude organic diseases in IBS, such as colonoscopy and blood tests, do not rule out SIBO. Several studies have reported the presence of SIBO in IBS patients in India as shown in Table 3[95,99-101]. Ghoshal et al reported that 19% of 80 IBS patients had SIBO, diagnosed by upper gut aspirate culture with a colony count > 105 CFU/ml[99]. In a case-control study among 225 Indian IBS patients, 11% had SIBO by glucose hydrogen breath test (GHBT) whereas 1% of 100 healthy subjects had SIBO[100]. In the third study, 9 (13%) of 69 IBS patients had SIBO by GHBT. There was no significant difference in the frequency of SIBO among subjects with and without lactose intolerance and IBS[101]. In the fourth study, 11 (8.5%) of 129 IBS subjects had SIBO compared to 1 (2%) of 51 healthy subjects[95]. An evidence-based review documented that the prevalence of SIBO in patients with IBS varies widely due to different criteria for defining a positive breath test and the methodology employed. It is 28%-84% with LHBT, 2%-31% with GHBT and 2%-6% based on culture[102]. Most of the studies used GHBT to diagnose SIBO in India. GHBT had a sensitivity and specificity of 44% and 82%, respectively when the culture of the upper gut aspirate was taken as the gold standard in a study on patients with malabsorption syndrome in India[103]. However, in a recent study on 80 patients with IBS (Rome III criteria), GHBT had a sensitivity of 27% and specificity of 100% considering quantitative jejunal aspirate culture as the gold standard[99]. The lower sensitivity of GHBT among patients with IBS as compared to malabsorption syndrome might be related to lower bacterial colony counts in proximal small bowel among former than the later group of patients.

Further evidence for the association between SIBO and IBS was provided by a randomized, placebo controlled trial from India, of norfloxacin in IBS cases with SIBO compared to those without SIBO. In this study, the response rate (negativity of Rome III criteria at 1 mo) of norfloxacin and placebo among IBS patients with and without SIBO was 87.5% (7/8) and 0% (0/7); 25% (8/32) and 0/33 (0%), respectively. Overall, 37.5% of 40 IBS patients responded to norfloxacin[99].

***Food intolerance including lactose malabsorption and IBS***

In the recent year, dietary fermentable oligo, di, monosaccharide, and polyols (FODMAP) have been incriminated in contributing to the symptoms of IBS[104]. However, studies on dietary FODMAP in the pathogenesis of IBS symptoms and their exclusion in its treatment have been scanty from India, Bangladesh, and Malaysia except for lactose as an isolated FODMAP. In a multi-centric Indian study, self-reported milk intolerance was present among 32% of 2785 subjects with lower gastrointestinal symptoms. Patients with IBS-D reported milk intolerance more often than those with IBS-C[10]. In a rural community-based study in Bangladesh, a regular dairy intake was present in 61.7% of 2542 subjects, but 13.8% reported milk intolerance. Among 593 subjects with IBS, 12.6% reported milk intolerance and they showed a higher frequency of frequent bowel motion and loose or watery stool (*p* < 0.025)[13]. However, the diagnostic accuracy of self-reported milk intolerance to diagnose lactose malabsorption was reported as having a sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) of 53%, 61%, 26%, and 55%, respectively in a case-control study in India among 112 IBS patients and 53 healthy controls[101]. In the same study, the frequency of lactose malabsorption diagnosed either by LHBT or LTT were similar among IBS (82%) and healthy controls (77%). Nevertheless, symptoms of lactose intolerance were more frequent among IBS (55%) compared to healthy subjects (34%). In an Indian study, authors demonstrated that lactose malabsorption diagnosed using 25-g lactose dose is clinically more meaningful than that diagnosed using conventional 50-g lactose dose, which is quite a non-physiological dose; in fact, lactose malabsorption diagnosed using 25-g lactose dose was associated with 10 times higher rate of clinical improvement following milk withdrawal than that diagnosed using 50-g dose[105]. More recently, investigators were able to demonstrate a similar frequency of C/T -13910 and G/A-22018 lactase gene polymorphism between Indian IBS patients and healthy controls[106]. These studies indicate that the prevalence of lactose malabsorption is high in South Asians, with no difference between IBS and non-IBS adults. However, the clinical consequences of lactose malabsorption are likely to be exaggerated in patients with IBS who often have underlying abnormalities in motility and visceral sensation and a reduced pain threshold. Of the other FODMAP agents, a northern Indian study showed that 14.4% patients with IBS, particularly IBS-D as compared to 2.4% of healthy controls had fructose malabsorption as demonstrated by fructose hydrogen breath test[107]. Importance of dietary factors in occurrence of IBS in the third world countries has been shown in a Brazilian study as well[108]. More studies on FODMAP diet and IBS their elimination in its treatment are needed from South Asia.

***Psychological co-morbidity and IBS***

With rapid development and urbanization in many of the South Asian countries including India, Malaysia, and Bangladesh, it is anticipated that an increase in urban-related psychopathology may contribute to IBS symptoms, severity and clinic visit in these nations. In a cross-sectional study of 248 adult patients in a referral center in Malaysia, a higher prevalence of anxiety and depression was observed in FD, NERD and IBS patients compared to a healthy control group (43.5%, 45.2% and 67.7% *vs* 14.5%, *P* < 0.001; and 22.6%, 33.9% and 38.7% *vs* 6.5%, *P* < 0.0001). IBS patients had a higher rate of anxiety than FD (*P* = 0.01) and NERD (*P* = 0.02), while no significant differences in depression rates were observed among all three groups of functional GI disorders[109].

In a similar study from India, a greater prevalence of major depressive (47.3% *vs* 5.1%; *p* < 0.001), somatoform (50% *vs* 14.6%; *p* < 0.001) and panic disorder (44% *vs* 11.6%; *p* < 0.001) were identified in IBS patients compared to healthy controls[110]. Whilst these studies in Malaysia and India have indicated an association between psychological disorders and IBS, a causal relationship could not be considered from these studies as patients with any chronic disorder are expected to have more psychological issues than healthy subjects. Furthermore, data on the efficacy of psychopharmacological therapy among Indian subjects with IBS have not been convincing. A prospective double blind randomized controlled study among 90 IBS patients showed that oxyphenonium bromide and imipramine was not superior to placebo in improving symptoms nor the health-related quality of life (*p* > 0.05)[111]. Nevertheless, about one-third of patients with lower GI symptoms in India were reported to be on tricyclic antidepressants in a previous survey[10].

***Healthcare seeking/consultation behavior***

Several community-based studies in India and Bangladesh have reported healthcare seeking behavior among IBS subjects in both rural and urban areas. Table 4 shows the consultation rates of IBS patients in India and Bangladesh. Physician consultation rates were 34.9%[13] and 65.5%[14] of IBS subjects in rural and urban Bangladesh, respectively with no significant gender differences (68.6%*vs* 61.2%, *p* > 0.05). The main predictor of consultation was the presence of multiple dyspeptic symptoms. The studies from India have alluded to a similarly high consultation rate (Table 4), with higher consultation rates for male IBS subjects (70% *vs* 44%, *p* = 0.00001)[9]. The types of healthcare practitioners consulted were explored in one study and found to include: physician of modern medicine (MBBS and above) 3.1%, homeopathic physicians 5%, ayurvedic physicians 8.3% and Unani practitioners 0.8%[12]. These studies from India and Bangladesh suggest that availability, accessibility, and cost of the consulting physician may be important determinants of the consultation behavior of the IBS patients.

**CONCLUSION**

This review has highlighted several unique aspects of IBS in the populations of India, Bangladesh, and Malaysia. The prevalence of IBS is comparable in urban and rural areas of these three countries. A male predominance has been reported in institution-based studies in India, but a gender disparity has not been observed in community studies. Upper abdominal symptoms and FD are common among IBS subjects in the community. The sensitivity of the Rome criteria to diagnose IBS is lower in India. Many patients with IBS cannot be subtyped into constipation- and diarrhea-predominant sub-types based on popularly used criteria developed in the West, and a stool subtype and the Asian criteria appear to be more sensitive. From a pathophysiological perspective, chronic gut infections, gut microbial dysbiosis, and SIBO appear to have important roles in IBS in South Asia. In spite of the high incidence of acute infective gastroenteritis, the low prevalence of IBS in India and Bangladesh remains somewhat enigmatic. PI-IBS, PI-MAS, and SIBO may have a great degree of overlap in adults may need specific investigations to differentiate them. Therefore, a role of the gut-specific antibiotic such as rifaximin can't be over-estimated. Healthcare consultation by IBS subjects in India and Bangladesh are high in both rural and urban areas.

***Future direction***

Further epidemiological studies using the same instruments and survey method are needed for valid comparison of the prevalence of IBS in the East and the West as well as a head to head comparison in the rural and urban areas in Asian countries. Further studies are also needed on the symptom profile and subtyping of IBS in Asian countries using clinical, Rome and Asian-based criteria. Considering the high burden of acute infectious diarrhea in the Indian Subcontinent and frequently reported cases of tropical sprue, more studies are needed on the pathophysiology of PI-IBS and PI-MAS.

**REFerENCES**

1 **Mearin F**, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. *Gastroenterology* 2016; Epub ahead of print [PMID: 27144627 DOI: 10.1053/j.gastro.2016.02.031]

2 **Agarwal N**, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. *Gastroenterol Clin North Am* 2011; **40**: 11-19 [PMID: 21333898 DOI: 10.1016/j.gtc.2010.12.013]

3 **El-Serag HB**, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. *Aliment Pharmacol Ther* 2002; **16**: 1171-1185 [PMID: 12030961 DOI: 10.1046/j.1365-2036.2002.01290]

4 **Lovell RM**, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. *Clin Gastroenterol Hepatol* 2012; **10**: 712-721.e4 [PMID: 22426087 DOI: 10.1016/j.cgh.2012.02.029]

5 **Sperber AD**, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, Hungin APS, Kang JY, Minhu C, Schmulson M, Bolotin A, Friger M, Freud T, Whitehead W. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. *Gut* 2017; **66**: 1075-1082 [PMID: 26818616 DOI: 10.1136/gutjnl-2015-311240]

6 **Drossman DA**, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. *Gastroenterology* 2002; **123**: 2108-2131 [PMID: 12454866]

7 **American College of Gastroenterology Task Force on Irritable Bowel Syndrome**, Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. *Am J Gastroenterol* 2009; **104** Suppl 1: S1-35 [PMID: 19521341 DOI: 10.1038/ajg.2008.122]

8 **Gwee KA**, Bak YT, Ghoshal UC, Gonlachanvit S, Lee OY, Fock KM, Chua AS, Lu CL, Goh KL, Kositchaiwat C, Makharia G, Park HJ, Chang FY, Fukudo S, Choi MG, Bhatia S, Ke M, Hou X, Hongo M; Asian Neurogastroenterology and Motility Association. Asian consensus on irritable bowel syndrome. *J Gastroenterol Hepatol* 2010; **25**: 1189-1205 [PMID: 20594245 DOI: 10.1111/j.1440-1746.2010.06353]

9 **Shah SS**, Bhatia SJ, Mistry FP. Epidemiology of dyspepsia in the general population in Mumbai. *Indian J Gastroenterol* 2001; **20**: 103-106 [PMID: 11400800]

10 **Ghoshal UC**, Abraham P, Bhatt C, Choudhuri G, Bhatia SJ, Shenoy KT, Banka NH, Bose K, Bohidar NP, Chakravartty K, Shekhar NC, Desai N, Dutta U, Das G, Dutta S, Dixit VK, Goswami BD, Jain RK, Jain S, Jayanthi V, Kochhar R, Kumar A, Makharia G, Mukewar SV, Mohan Prasad VG, Mohanty A, Mohan AT, Sathyaprakash BS, Prabhakar B, Philip M, Veerraju EP, Ray G, Rai RR, Seth AK, Sachdeva A, Singh SP, Sood A, Thomas V, Tiwari S, Tandan M, Upadhyay R, Vij JC. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. *Indian J Gastroenterol* 2008; **27**: 22-28 [PMID: 18541934]

11 **Makharia GK**, Verma AK, Amarchand R, Goswami A, Singh P, Agnihotri A, Suhail F, Krishnan A. Prevalence of irritable bowel syndrome: a community based study from northern India. *J Neurogastroenterol Motil* 2011; **17**: 82-87 [PMID: 21369496 DOI: 10.5056/jnm.2011.17.1.82]

12 **Ghoshal UC**, Singh R. Frequency and risk factors of functional gastro-intestinal disorders in a rural Indian population. *J Gastroenterol Hepatol* 2017; **32**: 378-387 [PMID: 27262283 DOI: 10.1111/jgh.13465]

13 **Masud MA**, Hasan M, Khan AK. Irritable bowel syndrome in a rural community in Bangladesh: prevalence, symptoms pattern, and health care seeking behavior. *Am J Gastroenterol* 2001; **96**: 1547-1552 [PMID: 11374697 DOI: 10.1111/j.1572-0241.2001.03760.x]

14 **Perveen I**, Hasan M, Masud MA, Bhuiyan MM, Rahman MM. Irritable bowel syndrome in a Bangladeshi urban community: prevalence and health care seeking pattern. *Saudi J Gastroenterol* 2009; **15**: 239-243 [PMID: 19794269 DOI: 10.4103/1319-3767.56099]

15 **Perveen I**, Rahman MM, Saha M, Rahman MM, Hasan MQ. Prevalence of irritable bowel syndrome and functional dyspepsia, overlapping symptoms, and associated factors in a general population of Bangladesh. *Indian J Gastroenterol* 2014; **33**: 265-273 [PMID: 24664445 DOI: 10.1007/s12664-014-0447-1]

16 **Rajendra S**, Alahuddin S. Prevalence of irritable bowel syndrome in a multi-ethnic Asian population. *Aliment Pharmacol Ther* 2004; **19**: 704-706 [PMID: 15023175 DOI: 10.1111/j.1365-2036.2004.01891.x]

17 **Lee YY**, Waid A, Tan HJ, Chua AS, Whitehead WE. Rome III survey of irritable bowel syndrome among ethnic Malays. *World J Gastroenterol* 2012; **18**: 6475-6480; discussion p. 6479 [PMID: 23197894 DOI: 10.3748/wjg.v18.i44.6475]

18 **Rajput M**, Saini SK. Prevalence of constipation among the general population: a community-based survey from India. *Gastroenterol Nurs* 2014; **37**: 425-429 [PMID: 25461464 DOI: 10.1097/SGA.0000000000000074]

19 **Rooprai R,** Bhat N, Sainani,R and Mayabhate MM. Prevalence of functional constipation and constipation-predominant irritable bowel syndrome in Indian patients with constipation. *Int J Basic Clin Pharmacol* 2017; **6**: 275-285 [DOI: 10.18203/2319-2003.ijbcp20170044]

20 **Chang FY**, Lu CL, Chen TS. The current prevalence of irritable bowel syndrome in Asia. *J Neurogastroenterol Motil* 2010; **16**: 389-400 [PMID: 21103420 DOI: 10.5056/jnm.2010.16.4.389]

21 **Pan G**, Lu S, Ke M, Han S, Guo H, Fang X. Epidemiologic study of the irritable bowel syndrome in Beijing: stratified randomized study by cluster sampling. *Chin Med J* (Engl) 2000; **113**: 35-39 [PMID: 11775207]

22 **Sperber AD**, Friger M, Shvartzman P, Abu-Rabia M, Abu-Rabia R, Abu-Rashid M, Albedour K, Alkranawi O, Eisenberg A, Kazanoviz A, Mazingar L, Fich A. Rates of functional bowel disorders among Israeli Bedouins in rural areas compared with those who moved to permanent towns. *Clin Gastroenterol Hepatol* 2005; **3**: 342-348 [PMID: 15822039]

23 **Usai P**, Manca R, Lai MA, Russo L, Boi MF, Ibba I, Giolitto G, Cuomo R. Prevalence of irritable bowel syndrome in Italian rural and urban areas. *Eur J Intern Med* 2010; **21**: 324-326 [PMID: 20603045 DOI: 10.1016/j.ejim.2010.05.009]

24 **Mahadeva S**, Yadav H, Everett SM, Goh KL. Factors influencing dyspepsia-related consultation: differences between a rural and an urban population. *Neurogastroenterol Motil* 2011; **23**: 846-853 [PMID: 21740483 DOI: 10.1111/j.1365-2982.2011.01746]

25 **Bordie AK**. Functional disorders of the colon. *J Indian Med Assoc* 1972; **58**: 451-456

26 **Mathur AK,** Tandon BN, Prakash OM. Irritable colon syndrome a clinical and laboratory study. *J Indian Med Assoc* 1966; **46**: 651-655

27 **Pimparkar BD**. Irritable Colon Syndrome. *J Indian Med Assoc* 1970; **54**: 95-105

28 **Lee OY**. Prevalence and risk factors of irritable bowel syndrome in Asia. *J Neurogastroenterol Motil* 2010; **16**: 5-7 [PMID: 20535320 DOI: 10.5056/jnm.2010.16.1.5]

29 **Choung RS**, Locke GR 3rd. Epidemiology of IBS. *Gastroenterol Clin North Am* 2011; **40**: 1-10 [PMID: 21333897 DOI: 10.1016/j.gtc.2010.12.006]

30 **Canavan C**, West J, Card T. The epidemiology of irritable bowel syndrome. *Clin Epidemiol* 2014; **6**: 71-80 [PMID: 24523597 DOI: 10.2147/CLEP.S40245]

31 **Venkataraman J,** Natrayan R and Varghese J. Can pain be an optional clinical criterion for irritable bowel syndrome. *Hungarian Med J* 2007; **1**: 133 [DOI: 10.1556/HMJ.1.2007.2.14]

32 **Kapoor KK**, Nigam P, Rastogi CK, Kumar A, Gupta AK. Clinical profile of irritable bowel syndrome. *Indian J Gastroenterol* 1985; **4**: 15-16 [PMID: 3843970]

33 **Ghoshal UC**, Abraham P, Bhatia SJ, Misra SP, Choudhuri G, Biswas KD, Chakravartty K, Dadhich S, Goswami BD, Jayanthi V, Kumar S, Koshy A, Kumar KR, Makharia G, Nijhawan S, Pratap N, Ray G, Sachdeva S, Singh SP, Thomas V, Udawat H. Comparison of Manning, Rome I, II, and III, and Asian diagnostic criteria: report of the Multicentric Indian Irritable Bowel Syndrome (MIIBS) study. *Indian J Gastroenterol* 2013; **32**: 369-375 [PMID: 23999682 DOI: 10.1007/s12664-013-0365-7]

34 **Perveen I,** Hasan M. Comparative prevalence of Iritable Bowel Syndrom (IBS) using multiple diagnostic criteria. *Bangladesh J Med* 2010; **21**: 1-6

35 **Banerjee R**, Choung OW, Gupta R, Tandan M, Lakhtakia S, Rao GV, Reddy DN. Rome I criteria are more sensitive than Rome II for diagnosis of irritable bowel syndrome in Indian patients. *Indian J Gastroenterol* 2005; **24**: 164-166 [PMID: 16204906]

36 **Mahadeva S**, Ford AC. Clinical and epidemiological differences in functional dyspepsia between the East and the West. *Neurogastroenterol Motil* 2016; **28**: 167-174 [PMID: 26331919 DOI: 10.1111/nmo.12657]

37 **Ghoshal UC**. Pros and Cons While Looking Through an Asian Window on the Rome IV Criteria for Irritable Bowel Syndrome: Pros. *J Neurogastroenterol Motil* 2017; **23**: 334-340 [PMID: 28672432 DOI: 10.5056/jnm17020]

38 **Siah KTH**, Gong X, Yang XJ, Whitehead WE, Chen M, Hou X, Pratap N, Ghoshal UC, Syam AF, Abdullah M, Choi MG, Bak YT, Lu CL, Gonlachanvit S, Boon CS, Fang F, Cheong PK, Wu JCY, Gwee KA. Rome Foundation-Asian working team report: Asian functional gastrointestinal disorder symptom clusters. *Gut* 2017; Epub ahead of print [PMID: 28592440 DOI: 10.1136/gutjnl-2016-312852]

39 **Ghoshal UC**, Gwee KA, Chen M, Gong XR, Pratap N, Hou X, Syam AF, Abdullah M, Bak YT, Choi MG, Gonlachanvit S, Chua AS, Chong KM, Siah KT, Lu CL, Xiong L, Whitehead WE. Development, Translation and Validation of Enhanced Asian Rome III Questionnaires for Diagnosis of Functional Bowel Diseases in Major Asian Languages: A Rome Foundation-Asian Neurogastroenterology and Motility Association Working Team Report. *J Neurogastroenterol Motil* 2015; **21**: 83-92 [PMID: 25537673 DOI: 10.5056/jnm14045]

40 **Rahman MM**, Ghoshal UC, Rowshon AH, Ahmed F, Kibria MG, Hasan M, Gwee KA, Whitehead WE. Translation and Validation of Enhanced Asian Rome III Questionnaires in Bengali Language for Diagnosis of Functional Gastrointestinal Disorders. *J Neurogastroenterol Motil* 2016; **22**: 240-247 [PMID: 26690730 DOI: 10.5056/jnm15129]

41 **Gwee KA**, Lu CL, Ghoshal UC. Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. *J Gastroenterol Hepatol* 2009; **24**: 1601-1607 [PMID: 19788601 DOI: 10.1111/j.1440-1746.2009.05984.x]

42 **Cremonini F**, Talley NJ. Review article: the overlap between functional dyspepsia and irritable bowel syndrome -- a tale of one or two disorders? *Aliment Pharmacol Ther* 2004; **20 Suppl 7**: 40-49 [PMID: 15521854 DOI: 10.1111/j.1365-2036.2004.02184.x]

43 **Gonlachanvit S**, Mahayosnond A, Kullavanijaya P. Effects of chili on postprandial gastrointestinal symptoms in diarrhoea predominant irritable bowel syndrome: evidence for capsaicin-sensitive visceral nociception hypersensitivity. *Neurogastroenterol Motil* 2009; **21**: 23-32 [PMID: 18647268 DOI: 10.1111/j.1365-2982.2008.01167.x]

44 **Mahadeva S**, Yadav H, Rampal S, Everett SM, Goh KL. Ethnic variation, epidemiological factors and quality of life impairment associated with dyspepsia in urban Malaysia. *Aliment Pharmacol Ther* 2010; **31**: 1141-1151 [PMID: 20175766 DOI: 10.1111/j.1365-2036.2010.04270.x]

45 **Fock KM**, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA; Second Asia-Pacific Conference. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. *J Gastroenterol Hepatol* 2009; **24**: 1587-1600 [PMID: 19788600 DOI: 10.1111/j.1440-1746.2009.05982.x]

46 **Fock KM**, Talley NJ, Fass R, Goh KL, Katelaris P, Hunt R, Hongo M, Ang TL, Holtmann G, Nandurkar S, Lin SR, Wong BC, Chan FK, Rani AA, Bak YT, Sollano J, Ho KY, Manatsathit S. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. *J Gastroenterol Hepatol* 2008; **23**: 8-22 [PMID: 18171339 DOI: 10.1111/j.1440-1746.2007.05249.x]

47 **Panigrahi MK**, Kar SK, Singh SP, Ghoshal UC. Defecation frequency and stool form in a coastal eastern Indian population. *J Neurogastroenterol Motil* 2013; **19**: 374-380 [PMID: 23875105 DOI: 10.5056/jnm.2013.19.3.374]

48 **Kibria MG,** Rahman MM, Ghoshal UC, Ahmed F, Sultana N, Akhter M, Hasan M.Defecation Frequency and Stool Form in a rural Community in Bangladesh. *J Neurogastroenterol Motil* 2015; **21**: s51

49 **Babu J**, Kumar S, Babu P, Prasad JH, Ghoshal UC. Frequency of lactose malabsorption among healthy southern and northern Indian populations by genetic analysis and lactose hydrogen breath and tolerance tests. *Am J Clin Nutr* 2010; **91**: 140-146 [PMID: 19889824 DOI: 10.3945/ajcn.2009.27946]

50 **Singh N**, Makharia GK, Joshi YK. Dietary survey and total dietary fiber intake in patients with irritable bowel syndrome attending a tertiary referral hospital. *Indian J Gastroenterol* 2008; **27**: 66-70 [PMID: 18695306]

51 Dietary Reference intakes for Energy, Carbohydrate, fiber, Fat, Fatty acids, Cholesterol, Protein, and Amino acids. Available from: url: <http://www.nationalacademies.org>

52 **British Nutrition foundation**. Dietary fibre- how much fibre do we need? Available from: url: <http://www.nutrition.org.uk>

53 **Lanza E**, Jones DY, Block G, Kessler L. Dietary fiber intake in the US population. *Am J Clin Nutr* 1987; **46**: 790-797 [PMID: 2823592]

54 **Tandon RK**, Prasad N, Gupta MC, Tandon BN. Stool weights and transit time in North Indians. *J Assoc Physicians India* 1976; **24**: 807-810 [PMID: 1028817]

55 **Vivinus-Nébot M**, Dainese R, Anty R, Saint-Paul MC, Nano JL, Gonthier N, Marjoux S, Frin-Mathy G, Bernard G, Hébuterne X, Tran A, Theodorou V, Piche T. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. *Am J Gastroenterol* 2012; **107**: 75-81 [PMID: 21931380 DOI: 10.1038/ajg.2011.315]

56 **Wouters MM**, Vicario M, Santos J. The role of mast cells in functional GI disorders. *Gut* 2016; **65**: 155-168 [PMID: 26194403 DOI: 10.1136/gutjnl-2015-309151]

57 **Sinagra E**, Pompei G, Tomasello G, Cappello F, Morreale GC, Amvrosiadis G, Rossi F, Lo Monte AI, Rizzo AG, Raimondo D. Inflammation in irritable bowel syndrome: Myth or new treatment target? *World J Gastroenterol* 2016; **22**: 2242-2255 [PMID: 26900287 DOI: 10.3748/wjg.v22.i7.2242]

58 **Bhuiyan MR**, Majumder TK, Raihan AA, Roy PK, Farha N, Kamal M. Histopathological alterations in post-infectious irritable bowel syndrome in Bangladeshi population. *Mymensingh Med J* 2010; **19**: 275-281 [PMID: 20395926]

59 **Barbara G**, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology* 2004; **126**: 693-702 [PMID: 14988823]

60 **Srivastava D**, Ghoshal U, Mittal RD, Ghoshal UC. Associations between IL-1RA polymorphisms and small intestinal bacterial overgrowth among patients with irritable bowel syndrome from India. *Neurogastroenterol Motil* 2014; **26**: 1408-1416 [PMID: 25073651 DOI: 10.1111/nmo.12399]

61 **Swan C**, Duroudier NP, Campbell E, Zaitoun A, Hastings M, Dukes GE, Cox J, Kelly FM, Wilde J, Lennon MG, Neal KR, Whorwell PJ, Hall IP, Spiller RC. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα. *Gut* 2013; **62**: 985-994 [PMID: 22684480 DOI: 10.1136/gutjnl-2011-301213]

62 **Saito YA**. The role of Genetics in IBS. *Gastroenterol Clin North Am* 2011; **40**: 45-47 [doi: 10.1016/j.gtc.2010.12.011]

63 **Park JM**, Choi MG, Park JA, Oh JH, Cho YK, Lee IS, Kim SW, Choi KY, Chung IS. Serotonin transporter gene polymorphism and irritable bowel syndrome. *Neurogastroenterol Motil* 2006; **18**: 995-1000 [PMID: 17040410 DOI: 10.1111/j.1365-2982.2006.00829.x]

64 **Makker J**, Chilimuri S, Bella JN. Genetic epidemiology of irritable bowel syndrome. *World J Gastroenterol* 2015; **21**: 11353-11361 [PMID: 26525775 DOI: 10.3748/wjg.v21.i40.11353]

65 **Barbara G**, Feinle-Bisset C, Ghoshal UC, Quigley EM, Santos J, Vanner S, Vergnolle N, Zoetendal EG. The Intestinal Microenvironment and Functional Gastrointestinal Disorders. *Gastroenterology* 2016; Epub ahead of print [PMID: 27144620 DOI: 10.1053/j.gastro.2016.02.028]

66 **Kumar S**, Ranjan P, Mittal B, Ghoshal UC. Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls. *J Gastrointestin Liver Dis* 2012; **21**: 31-38 [PMID: 22457857]

67 **Kamp EJ**, Kane JS, Ford AC. Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2016; **14**: 659-68.e1; quiz e54-5 [PMID: 26453949 DOI: 10.1016/j.cgh.2015.09.031]

68 **Rahman MA**, Raihan AS, Ahamed DS, Masud H, Safiullah AB, Khair KB, Salimullah AS, Islam MM. Symptomatic overlap in patients with diarrhea predominant irritable bowel syndrome and microscopic colitis in a sub group of Bangladeshi population. *Bangladesh Med Res Counc Bull* 2012; **38**: 33-38 [PMID: 22545349]

69 **Hilmi I**, Hartono JL, Pailoor J, Mahadeva S, Goh KL. Low prevalence of 'classical' microscopic colitis but evidence of microscopic inflammation in Asian irritable bowel syndrome patients with diarrhoea. *BMC Gastroenterol* 2013; **13**: 80 [PMID: 23651739 DOI: 10.1186/1471-230X-13-80]

70 **Falodia S**, Makharia GK, Sateesh J, Deo V, Tevatia MS, Gupta SD. Spectrum of microscopic colitis in a tertiary care centre in India. *Trop Gastroenterol* 2007; **28**: 121-125 [PMID: 18384001]

71 **Misra V**, Misra SP, Dwivedi M, Singh PA, Agarwal V. Microscopic colitis in patients presenting with chronic diarrhea. *Indian J Pathol Microbiol* 2010; **53**: 15-19 [PMID: 20090215 DOI: 10.4103/0377-4929.59176]

72 **Ng SC**, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, Wong TC, Leung VK, Tsang SW, Yu HH, Li MF, Ng KK, Kamm MA, Studd C, Bell S, Leong R, de Silva HJ, Kasturiratne A, Mufeena MN, Ling KL, Ooi CJ, Tan PS, Ong D, Goh KL, Hilmi I, Pisespongsa P, Manatsathit S, Rerknimitr R, Aniwan S, Wang YF, Ouyang Q, Zeng Z, Zhu Z, Chen MH, Hu PJ, Wu K, Wang X, Simadibrata M, Abdullah M, Wu JC, Sung JJ, Chan FK; Asia–Pacific Crohn's and Colitis Epidemiologic Study (ACCESS) Study Group. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. *Gastroenterology* 2013; **145**: 158-165.e2 [PMID: 23583432 DOI: 10.1053/j.gastro.2013.04.007]

73 **Anand AC**, Reddy PS, Saiprasad GS, Kher SK. Does non-dysenteric intestinal amoebiasis exist? *Lancet* 1997; **349**: 89-92 [PMID: 8996420]

74 **Sinha P**, Ghoshal UC, Choudhuri G, Naik S, Ayyagari A, Naik SR. Does Entamoeba histolytica cause irritable bowel syndrome? *Indian J Gastroenterol* 1997; **16**: 130-133 [PMID: 9357182]

75 **Ragavan ND**, Kumar S, Chye TT, Mahadeva S, Shiaw-Hooi H. Blastocystis sp. in Irritable Bowel Syndrome (IBS)--Detection in Stool Aspirates during Colonoscopy. *PLoS One* 2015; **10**: e0121173 [PMID: 26375823 DOI: 10.1371/journal.pone.0121173]

76 **Ragavan ND**, Govind SK, Chye TT, Mahadeva S. Factors that influence the shedding of Blastocystis cysts in an irritable bowel syndrome (IBS) patient--an evidence-based case study. *Parasitol Res* 2015; **114**: 2999-3005 [PMID: 25982571 DOI: 10.1007/s00436-015-4502-3]

77 **Nayak AK**, Karnad DR, Abraham P, Mistry FP. Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called 'chronic amebiasis'. *Indian J Gastroenterol* 1997; **16**: 137-139 [PMID: 9357184]

78 **Roy E,** Hasan KZ, Haque R, Fazlul Haque AKM, Siddique AK, et al. Patterns and risk factors for helminthiasis in rural children aged under 2 in Bangladesh. *SAJCH S Afr J Child Health* 2011; **5**: 78-84

79 **Kang G**, Mathew MS, Rajan DP, Daniel JD, Mathan MM, Mathan VI, Muliyil JP. Prevalence of intestinal parasites in rural Southern Indians. *Trop Med Int Health* 1998; **3**: 70-75 [PMID: 9484973 DOI: 10.1046/j.1365-3156.1998.00175.x]

80 **Glatman Zaretsky A**, Taylor JJ, King IL, Marshall FA, Mohrs M, Pearce EJ. T follicular helper cells differentiate from Th2 cells in response to helminth antigens. *J Exp Med* 2009; **206**: 991-999 [PMID: 19380637 DOI: 10.1084/jem.20090303]

81 **Shi HN**, Ingui CJ, Dodge I, Nagler-Anderson C. A helminth-induced mucosal Th2 response alters nonresponsiveness to oral administration of a soluble antigen. *J Immunol* 1998; **160**: 2449-2455 [PMID: 9498789]

82 **Bercik P**, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? *Gastroenterol Clin North Am* 2005; **34**: 235-245, vi-vii [PMID: 15862932 DOI: 10.1016/j.gtc.2005.02.007]

83 **Ghoshal UC**, Park H, Gwee KA. Bugs and irritable bowel syndrome: The good, the bad and the ugly. *J Gastroenterol Hepatol* 2010; **25**: 244-251 [PMID: 20074148 DOI: 10.1111/j.1440-1746.2009.06133.x]

84 **Spiller R**, Garsed K. Postinfectious irritable bowel syndrome. *Gastroenterology* 2009; **136**: 1979-1988 [PMID: 19457422 DOI: 10.1053/j.gastro.2009.02.074]

85 **Thabane M**, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. *Aliment Pharmacol Ther* 2007; **26**: 535-544 [PMID: 17661757 DOI: 10.1111/j.13652036.2007.03399.x]

86 **Ghoshal UC**, Ranjan P. Post-infectious irritable bowel syndrome: the past, the present and the future. *J Gastroenterol Hepatol* 2011; **26** Suppl 3: 94-101 [PMID: 21443719 DOI: 10.1111/j.1440-1746.2011]

87 **Wang LH**, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. *Gut* 2004; **53**: 1096-1101 [PMID: 15247174 DOI: 10.1136/gut.2003.021154]

88 **Ji S**, Park H, Lee D, Song YK, Choi JP, Lee SI. Post-infectious irritable bowel syndrome in patients with Shigella infection. *J Gastroenterol Hepatol* 2005; **20**: 381-386 [PMID: 15740480 DOI: 10.1111/j.1440-1746.2005]

89 **Mathan VI**, Rajan DP. The prevalence of bacterial intestinal pathogens in a healthy rural population in southern India. *J Med Microbiol* 1986; **22**: 93-96 [PMID: 3746876 DOI: 10.1099/00222615-22-2-93]

90 **Islam MS**, Bhuiya A, Yunus M. Socioeconomic differentials of diarrhoea morbidity and mortality in selected villages of Bangladesh. *J Diarrhoeal Dis Res* 1984; **2**: 232-237 [PMID: 6530532]

91 **Rahaman MM**, Aziz KM, Munshi MH, Patwari Y, Rahman M. A diarrhea clinic in rural Bangladesh: influence of distance, age, and sex on attendance and diarrheal mortality. *Am J Public Health* 1982; **72**: 1124-1128 [PMID: 7114335]

92 **Mathan VI**, Baker SJ. Epidemic tropical sprue and other epidemics of diarrhea in South Indian villages. *Am J Clin Nutr* 1968; **21**: 1077-1087 [PMID: 5675846]

93 **Ghoshal UC**, Srivastava D, Verma A, Ghoshal U. Tropical sprue in 2014: the new face of an old disease. *Curr Gastroenterol Rep* 2014; **16**: 391 [PMID: 24781741 DOI: 10.1007/s11894-014-0391-3]

94 **Ghoshal UC**, Ghoshal U, Ayyagari A, Ranjan P, Krishnani N, Misra A, Aggarwal R, Naik S, Naik SR. Tropical sprue is associated with contamination of small bowel with aerobic bacteria and reversible prolongation of orocecal transit time. *J Gastroenterol Hepatol* 2003; **18**: 540-547 [PMID: 12702046 DOI: 10.1046/j.1440-1746.2003]

95 **Ghoshal UC**, Kumar S, Mehrotra M, Lakshmi C, Misra A. Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea. *J Neurogastroenterol Motil* 2010; **16**: 40-46 [PMID: 20535325 DOI: 10.5056/jnm.2010.16.1.40]

96 **Ghoshal UC**, Gwee KA. Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: the missing link. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 435-441 [PMID: 28513629 DOI: 10.1038/nrgastro.2017.37]

97 **McCarroll MG**, Riddle MS, Gutierrez RL, Porter CK. Infectious Gastroenteritis as a Risk Factor for Tropical Sprue and Malabsorption: A Case-Control Study. *Dig Dis Sci* 2015; **60**: 3379-3385 [PMID: 26115751 DOI: 10.1007/s10620-015-3768-8]

98 **Rahman MM,** Ghoshal UC, Sultana S, Kibria MG, Sultana N, Khan ZA, Ahmed F, Hasan M, Ahmed T, Sarker SA. Long-term gastrointestinal consequences are frequent following sporadic acute infectious diarrhea in a tropical country: A prospective cohort study. *J Neurogastroenterol motil* 2017; **23**: 208

99 **Ghoshal UC**, Srivastava D, Misra A, Ghoshal U. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. *Eur J Gastroenterol Hepatol* 2016; **28**: 281-289 [PMID: 26731696 DOI: 10.1097/MEG.0000000000000557]

100 **Rana SV**, Sinha SK, Sikander A, Bhasin DK, Singh K. Study of small intestinal bacterial overgrowth in North Indian patients with irritable bowel syndrome: a case control study. *Trop Gastroenterol* 2008; **29**: 23-25 [PMID: 18564663]

101 **Gupta D**, Ghoshal UC, Misra A, Misra A, Choudhuri G, Singh K. Lactose intolerance in patients with irritable bowel syndrome from northern India: a case-control study. *J Gastroenterol Hepatol* 2007; **22**: 2261-2265 [PMID: 17559357 DOI: 10.1111/j.1440-1746.2007]

102 **Schmulson M**, Bielsa MV, Carmona-Sánchez R, Hernández A, López-Colombo A, López Vidal Y, Peláez-Luna M, Remes-Troche JM, Tamayo JL, Valdovinos MA. Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review. *Rev Gastroenterol Mex* 2014; **79**: 96-134 [PMID: 24857420 DOI: 10.1016/j.rgmx.2014.01.004]

103 **Ghoshal UC**, Ghoshal U, Das K, Misra A. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome and its relationship with oro-cecal transit time. *Indian J Gastroenterol* 2006; **25**: 6-10 [PMID: 16567886]

104 **Staudacher HM**, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. *Gut* 2017; **66**: 1517-1527 [PMID: 28592442 DOI: 10.1136/gutjnl-2017-313750]

105 **Ghoshal UC**, Kumar S, Misra A, Mittal B. Lactose malabsorption diagnosed by 50-g dose is inferior to assess clinical intolerance and to predict response to milk withdrawal than 25-g dose in an endemic area. *J Gastroenterol Hepatol* 2013; **28**: 1462-1468 [PMID: 23701423 DOI: 10.1111/jgh.12273]

106 **Kumar S**, Ranjan P, Mittal B, Singh R, Ghoshal UC. Lactase persistence/non-persistence genetic variants in irritable bowel syndrome in an endemic area for lactose malabsorption. *J Gastroenterol Hepatol* 2012; **27**: 1825-1830 [PMID: 22989008 DOI: 10.1111/j.1440-1746.2012]

107 **Sharma A**, Srivastava D, Verma A, Misra A, Ghoshal UC. Fructose malabsorption is not uncommon among patients with irritable bowel syndrome in India: a case-control study. *Indian J Gastroenterol* 2014; **33**: 466-470 [PMID: 25066182 DOI: 10.1007/s12664-014-0492-9]

108 **Soares RL**, dos Santos JM, Rocha VR. Prevalence of irritable bowel syndrome in a Brazilian Amazon community. *Neurogastroenterol Motil* 2005; **17**: 883 [PMID: 16336505]

109 **Hartono JL**, Mahadeva S, Goh KL. Anxiety and depression in various functional gastrointestinal disorders: do differences exist? *J Dig Dis* 2012; **13**: 252-257 [PMID: 22500787 DOI: 10.1111/j.1751-2980.2012]

110 **Singh P**, Agnihotri A, Pathak MK, Shirazi A, Tiwari RP, Sreenivas V, Sagar R, Makharia GK. Psychiatric, somatic and other functional gastrointestinal disorders in patients with irritable bowel syndrome at a tertiary care center. *J Neurogastroenterol Motil* 2012; **18**: 324-331 [PMID: 22837881 DOI: 10.5056/jnm.2012.18.3.324]

111 **Uddin MJ,** Banik RK, Kabir MA, Bhuiyan MM, Miah MA, Raihan AS, Roy PK, Hasan M. Efficacy of oxyphenonium bromide and imipramine in Irritable bowel syndrome. *Bangladesh J Med* 2005; **16**: 25-31

**P-Reviewer:** Chiba T, De Ponti F, Jadallah KA, Pan W, Soares RL

**S-Editor:** Gong ZM **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** India

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Prevalence of irritable bowel syndrome in India, Bangladesh and Malaysia**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study site** | **Sample size** | **Study type** | **Criteria** | **Prevalence** | **Male/female ratio** |
| Shah *et al*[9]  | Mumbai, IndiaUrban | 2549 | community/healthy subjects | Manning | 7.5% | 1/0.87 |
| Ghoshal *et al*[10]  | Multiple sites, India | 4500 | community | Clinical | 4.2% | 1/0.93 |
| Makharia *et al*[11] | Haryana, India | 4767 | community | Rome III | 4% | 1/1.5 |
| Ghoshal *et al*[12] | Uttar Pradesh, India, rural | 2876 | community | Rome III | 6.8% | 1/1.09 |
| Masud *et al*[13] | Natore,BangladeshRural | 2426 | community | Rome I | 8.5% | 1/1.84 |
| Perveen *et al*[14] | Dhaka, Bangladesh, urban | 1503 | community | Rome II | 7.7% | 1/1.28 |
| Perveen *et al*[15] | Sylthet,Bangladeshurban and rural | 3000 | community | Rome III | 12.9% | 1/1.09 |
| Rajendra *et al*[16] | West coast, Malaysia, urban | 1179 | community | Rome II | 14% | 1/1.4 |
| Lee *et al*[17] | East coast, Malaysiarural |  | Community | Rome III | 10.9% | 1/1.18 |

**Table 2 Rome III and Rome IV criteria for diagnosis of irritable bowel syndrome[37]**

|  |  |
| --- | --- |
| **Rome III criteria** | **Rome IV criteria** |
| At least 3 mo, with onset at least 6 mo previously of recurrent (at least 3 d/mo) abdominal pain or discomfort associated with 2 or more of the followings | Recurrent abdominal pain, on average, at least 1 d per week in the last 3 mo, associated with 2 or more of the followings |
| Improvement with defecation  | Related to defecation |
| Onset associated with a change of frequency of stool  | Associated with a change in frequency of stool  |
| Onset associated with a change in form of stool | Associated with a change in form (appearance) of stool |

Differences between Rome III and IV criteria are highlighted using bold letters.

**Table 3 Studies on small intestinal bacterial overgrowth in India**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Number of IBS patients** | **Diagnostic criteria of IBS** | **Number of controls** | **Method of diagnosis of SIBO** | **% of SIBO in IBS** | **% of SIBO in controls** |
| Ghoshal *et al*[99] | 80 | Rome III | \_ | Cultute of upper jejunal aspirate | 19% | - |
| Rana *et al*[100] | 225 | Rome II | 100 | GHBT | 11.1 | 1 |
| Gupta *et al*[101] | 69 | Rome II | - | GHBT | 13 | \_ |
| Ghoshal *et al*[95] | 129 | Manning | 51 | GHBT | 8.5 | 2 |

SIBO: small intestinal bacterial overgrowth;IBS: irritable bowel syndrome; GHBT: glucose hydrogen breath test.

**Table 4 Consultation rate of IBS patients in different population-based studies in India and Bangladesh**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study areas/ country** | **Number of IBS patients** | **Diagnostic criteria of IBS** | **Consultation****Rate** | **Reason of consultation** | **Nature of consulting doctors** |
| Shah *et al*[9]  | Urban/India | 190 | Manning | 28.94 | \_ | \_ |
| Ghoshal *et al*[12] | Rural/India | FGIDs | Rome III | 17.2% | - | MBBS and above (3.1%)Homeopathic (5%)Ayuervadic (8.3%)Unani (0.8%) |
| Masud *et al*[13] | Rural/Bangladesh | 593 | Manning | 39% | Altered stool passageSense of incomplete evacuationMucus in stool |  |
| Irin *et al*[14] | Urban/Bangladesh | 116 | Rome II | 65.5% | Multiple dyspeptic symptoms |  |

IBS: irritable bowel syndrome; FGIDs: Functional gastrointestinal disorders.



**Figure 1** **Map of India, Bangladesh and Malaysia showing sites of epidemiological studies on IBS in these countries and its prevalence.** IBS: irritable bowel syndrome; R: rural; U: urban.

**Figure 2 Prevalence of irritable bowel syndrome, dyspepsia and overlap syndromes in community studies in Indian and Bangladesh.** IBS: irritable bowel syndrome.